Severn Biotech Signals Firm Footing with Site Expansion

Severn Biotech Ltd, manufacturer of Synthetic Peptides and Laboratory Reagent products, has announced the recent acquisition of Unit 1 Park Lane Kidderminster. The additional building, covering over 4000Sq ft, reflects the company’s expansion plans going forward and its need to increase the Laboratory space necessary to develop new products and services.

With the existing premises, the additional building gives a combined total of over 8000 sq ft, divided into manufacturing production laboratories, quality control, packaging, storage, distribution and sales.

 Unit 1 will initially be used for packaging and storage, with the development of further laboratories and a clean room facility at a later stage. The investment made by its founding Managing Director Andrew Smart, MSc. M.IoD.  is part of a £250K funding development package of private capital necessary to take the firm to the next level within the company’s business plan.

Severn Biotech manufactures research products, synthetic peptides, conjugates and biological/ immunological molecules used in antibody formation. The development of new sterile products, cell biology buffers and laboratory consumables for life science researchers represents continued investment in new products and processes.